EGFR and non-small cell lung carcinoma: Osimertinib, a third‐generation EGFR TKI, has exhibited superior therapeutic outcomes in the management of EGFR‐mutant NSCLC, extending the overall survival of patients from less than 12 months to 3 years or more.[5, 6] In parallel, immune checkpoint inhibitors (ICIs), including pembrolizumab and nivolumab, have also yielded significant clinical benefits in the treatment of advanced NSCLC, leading to durable tumor responses and increased survival rates.[7, 8] Despite the advancements in these therapeutic modalities, there is considerable room for improvement.